World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
144
Citations
71526
World Ranking
1452
National Ranking
848

Teru Hideshima publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Teru Hideshima sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 727 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Teru Hideshima D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Teru Hideshima sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 144 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Teru Hideshima is affiliated with Harvard University in the United States and has focused their research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans multiple areas with notable concentration in molecular biology, hematology, oncology, immunology, and pathology and forensic medicine as subfields of study.

Their research topics include the investigation of multiple myeloma research and treatments, protein degradation and inhibitors, peptidase inhibition and analysis, ubiquitin and proteasome pathways, cancer mechanisms and therapy, immunotherapy and immune responses, and immune cell function and interaction.

Frequent publication venues for Hideshima's work include Blood, Cancer Research, Clinical Lymphoma Myeloma & Leukemia, Leukemia, and Blood Cancer Journal.

Among their recent scientific papers are:

  • Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation, 2021, Blood Cancer Discovery
  • The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications, 2020, Blood
  • Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma, 2021, Leukemia
  • Signaling Pathway Mediating Myeloma Cell Growth and Survival, 2021, Cancers
  • Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways, 2020, Leukemia

Hideshima collaborates frequently with researchers such as Kenneth C. Anderson, Yu-Tzu Tai, Nikhil C. Munshi, Kenneth Wen, and Annamaria Gullà. These partnerships are reflected in the number of coauthored publications and contribute to the breadth of their research scope.

Best Publications

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

    Teru Hideshima;Paul Richardson;Dharminder Chauhan;Vito J. Palombella

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • NF-κB as a Therapeutic Target in Multiple Myeloma *

    Teru Hideshima;Dharminder Chauhan;Paul Richardson;Constantine Mitsiades

  • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

    Teru Hideshima;Constantine Mitsiades;Giovanni Tonon;Paul G. Richardson

  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

    Paul G. Richardson;Robert L. Schlossman;Robert L. Schlossman;Edie Weller;Edie Weller;Teru Hideshima;Teru Hideshima

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Molecular sequelae of proteasome inhibition in human multiple myeloma cells

    Nicholas Mitsiades;Constantine S. Mitsiades;Vassiliki Poulaki;Dharminder Chauhan

  • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

    Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Vassiliki Poulaki

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

    Nicholas Mitsiades;Constantine S. Mitsiades;Vassiliki Poulaki;Dharminder Chauhan

  • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

    Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar

  • Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

    S. Vincent Rajkumar;Paul G. Richardson;Teru Hideshima;Kenneth C. Anderson

  • Advances in biology of multiple myeloma: clinical applications

    Teru Hideshima;P. Leif Bergsagel;W. Michael Kuehl;Kenneth C. Anderson

  • Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

    Constantine S Mitsiades;Nicholas S Mitsiades;Nicholas S Mitsiades;Ciaran J McMullan;Vassiliki Poulaki;Vassiliki Poulaki

  • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

    Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi

  • Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

    Teru Hideshima;James E. Bradner;Jason Wong;Dharminder Chauhan

  • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

    Constantine S. Mitsiades;Nicholas S. Mitsiades;Ciaran J. McMullan;Vassiliki Poulaki

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

Frequent Co-Authors

Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Noopur Raje
Noopur Raje Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Klaus Podar
Klaus Podar Karl Landsteiner University of Health Sciences
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Robert L. Schlossman
Robert L. Schlossman Harvard University
Irene M. Ghobrial
Irene M. Ghobrial Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA isn’t limited to traditional medical school routes. Many students consider alternative degrees and certifications that provide entry into healthcare fields with more flexible study options and cost-effective pathways.

For those seeking a quick start, how much is medical billing and coding school is a common question. Medical billing and coding programs are popular because they offer fast, online training at lower costs, leading to administrative roles in clinics and hospitals.

Nursing remains one of the most in-demand professions. If you’re interested in advanced practice, you might explore the cheapest online np programs. These programs prepare registered nurses to become nurse practitioners, a high-responsibility healthcare role with strong job prospects.

For foundational nursing education, there are many affordable nursing programs available online, making it easier to earn your degree on a budget. Ambitious professionals may also consider online phd nursing programs to open doors in research, academia, or leadership.

These online degree and certificate pathways offer flexible, affordable options for entering and advancing in the healthcare field—helping you achieve your career goals beyond traditional medical school.

Best Scientists Citing Teru Hideshima

Trending Scientists

Recently Published Articles